Crossmark

The case for investing in provider-administered subcutaneous DMPA: a costing study

Crossref DOI link: https://doi.org/10.1136/bmjgh-2024-018761

Published Online: 2025-10-23

Published Print: 2025-10

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Burke, Holly M https://orcid.org/0000-0002-5538-5628
Ng'ambi, Wingston Felix

Homan, Rick

Lydon, Megan M https://orcid.org/0000-0001-8417-8735
Chirwa, Jessie Salamba

Kachule, Hannah

Jabu, Grace

Chen, Mario
Funding

Funding for this research was provided by:

Bill and Melinda Gates Foundation (INV-051705)

Children’s Investment Fund Foundation (2210-08121)
License Information

License valid from 2025-10-22